MedPath

Study to evaluate the efficacy of Dhanyamla Dhara in Diabetic Neuropathy

Phase 1
Conditions
Health Condition 1: G64- Other disorders of peripheral nervous system
Registration Number
CTRI/2023/08/056952
Lead Sponsor
DR VAIDYANATH V.S
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Metabolically stable diabetic subjects with symptomatic Diabetic Peripheral Neuropathy.

2.Subjects of all gender between the age group of 30-65 years.

3.Subjects fulfilling the diagnostic criteria.

4.Subjects whose HbA1C is between 6.5 to 10%.

Exclusion Criteria

1.Subjects where HbA1C >10% and <6.5%.

2.Subjects suffering from Type-1 Diabetes or Gestational Diabetes.

3.Pregnant and lactating women.

4.Subjects suffering from infectious diseases and non-healing ulcer/ ulcers of foot.

5.Any systemic illness that can interfere with the course of treatment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of the patients condition will be done based on <br/ ><br>1.Changes in Michigan Neuropathy Screening Instrument (MNSI) Questionnaire score <br/ ><br>2.Changes in Toronto Neuropathy Clinical Scale (TCNS) Score <br/ ><br>3.Changes in Visual Analog Scale (VAS) <br/ ><br>Timepoint: Before intervention 0th day <br/ ><br>After intervention 7th day <br/ ><br>Follow up 14th day
Secondary Outcome Measures
NameTimeMethod
1. Changes in FBS value <br/ ><br>2. Changes in PPBS valueTimepoint: Before intervention 0th day <br/ ><br>After intervention 7th day <br/ ><br>Follow up 14th day
Âİ Copyright 2025. All Rights Reserved by MedPath